Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
13. Januar 2025 07:00 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
Regenerative Medicine Research Report 2024-2031: Approvals for New Regenerative Medicines and Increasing Applications of Regenerative Medicine in Newer Therapy Areas Driving the $37.27 Billion Market
19. Dezember 2024 05:24 ET
|
Research and Markets
Dublin, Dec. 19, 2024 (GLOBE NEWSWIRE) -- The "Regenerative Medicine Market Size, Share, Forecast, & Trends Analysis by Product Application End User - Global Forecast to 2031" report has been...
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
12. November 2024 16:01 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
Oral Proteins & Peptides Market Research: Semaglutide, Linaclotide, Calcitonin,GLP-1 Receptor Agonist, GEP, CGRP, Diabetes, Gastroenterology, Genetic Disorder - Global Forecast to 2029
08. November 2024 11:32 ET
|
Research and Markets
Dublin, Nov. 08, 2024 (GLOBE NEWSWIRE) -- The "Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic...
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
06. November 2024 16:05 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
29. Oktober 2024 07:46 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
29. Oktober 2024 07:45 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of Regimen Following Islet Transplantation
Renown Health Welcomes First Kidney Transplant Surgeon & Chief of Transplant Surgery Program
10. Oktober 2024 14:42 ET
|
Renown Health
Reno, NEV., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Renown Health announces the appointment of Ernesto P. Molmenti, M.D., PH.D. M.B.A. as the hospital’s inaugural kidney transplant surgeon, Chief of...
Renown Welcomes the First Transplant Nephrologist to Region & Announces Renown Transplant Institute
03. Oktober 2024 17:26 ET
|
Renown Health
Reno, NEV., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Renown Health is pleased to announce the appointment of Narisorn Atsava-Svate, MD, a distinguished transplant nephrologist. With over 18 years of...
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
11. September 2024 16:05 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference